Fsme Impfung

https://www.who.int › health-topics › tick-borne-encephalitis
Tick borne encephalitis TBE is an important cause of viral infections of the central nervous system in eastern central northern and increasingly western European countries and in

https://www.who.int › news › item
Immunization offers the most effective protection against tick borne encephalitis Currently there are four widely used vaccines of assured quality FSME Immun and Encepur

https://www.who.int › docs › default-source › immunization › posi…
With FSME IMMUN Junior the seropositivity rates as determined by NT 28 days after the second vaccination were 100 0 in all three age groups 1 2 3 6 and 7 11 years

https://www.who.int › docs › default-source › immunization › posi…
In 2009 Leonova GN et al compared the immunogenicity in adults of TBE Moscow EnceVir and the two Western vaccines FSME IMMUN and Encepur adults Immunogenicity was measured 2 5

https://www.who.int › teams › health-product-policy-and-standards › ...
Unlike chemical drugs many biological preparations are unstable during storage and this instability can reduce the safety and efficacy of the biological medicinal product

https://www.who.int › docs › default-document...
kontrollieren Sie Kleidung und Haut regelm ig auf Zecken insbesondere nach Aktivit ten im Freien len bei denen ein Kontakt mit Zecken wahrscheinlich ist Eine bersicht ber die aktuellen FSME

https://www.who.int › docs › default-source › immunization › tabl…
National schedules should be based on local epidemiologic programmatic resource policy considerations While vaccines are universally recommended some children may have

https://www.who.int › docs › default-source › immunization › tabl…
Summary Table 3 Notes The attached table summarizes the WHO recommendations for interrupted or delayed routine vaccination Its purpose is to assist national decision makers and programme

https://www.who.int › publications › item › guidelines-on-stability...
Publications of the World Health OrganizationHome Publications Overview Guidelines on Stability Evaluation of Vaccines Annex 3 TRS No 962